Pui C H, Jackson C W, Chesney C, Lyles S A, Bowman W P, Abromowitch M, Simone J V
J Clin Oncol. 1983 Jun;1(6):380-5. doi: 10.1200/JCO.1983.1.6.380.
Coagulation and platelet function in 13 children with acute lymphoblastic leukemia were studied sequentially during a remission induction with L-asparaginase, prednisone, and vincristine. In the first weeks of therapy, which included four doses of L-asparaginase coagulation was characterized by significant decreases in plasma concentrations of plasminogen, antithrombin III alpha 2-macroglobulin, and fibrinogen. All measures gradually returned to normal after complication of L-asparaginase therapy. In the latter part of induction treatment, clotting times, especially partial Thromboplastin time, decreased significantly, while levels of factors V and VIII increased with recovery of platelet counts. At this time, 6 patients had an increased in vitro platelet aggregation response to adenosine diphosphate, and their partial thromboplastin times were significantly shorter than those of patients without increased aggregation. Concurrent abnormalities in coagulation and platelet function may account for the thrombotic complications that develop in some children receiving induction therapy with these agents.
对13例急性淋巴细胞白血病患儿在使用L-天冬酰胺酶、泼尼松和长春新碱进行缓解诱导治疗期间的凝血和血小板功能进行了序贯研究。在治疗的最初几周,包括四剂L-天冬酰胺酶,凝血的特征是血浆中纤溶酶原、抗凝血酶III、α2-巨球蛋白和纤维蛋白原浓度显著降低。L-天冬酰胺酶治疗出现并发症后,所有指标逐渐恢复正常。在诱导治疗后期,凝血时间,尤其是部分凝血活酶时间显著缩短,而随着血小板计数恢复,因子V和VIII水平升高。此时,6例患者对二磷酸腺苷的体外血小板聚集反应增强,且其部分凝血活酶时间明显短于未增强聚集反应的患者。凝血和血小板功能的并发异常可能是一些接受这些药物诱导治疗的儿童发生血栓并发症的原因。